Last reviewed · How we verify
Nebulize %3 Sodium Chloride
At a glance
| Generic name | Nebulize %3 Sodium Chloride |
|---|---|
| Also known as | %3 NaCl |
| Sponsor | Sakarya University |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- White blood cell count increased
- Covid-19
- Rhinovirus Infection
- Pain in Jaw
- Headache
- Depression
- Epistaxis
- Nasal Discomfort
- Erythema
- Heart Rate Increased
- Dysgeusia
Key clinical trials
- The Effect of NAC on Lung Function and CT Mucus Score (PHASE4)
- Nebulised Colistimethate Sodium to Prevent Pediatric Ventilator-associated Pneumonia (PHASE2, PHASE3)
- Platform of Randomized Adaptive Clinical Trials in Critical Illness (NA)
- Efficacy Of Combined Nebulized Hypertonic Saline and Chest Percussion Therapy in Acute Viral Bronchiolitis (PHASE4)
- Predicting Post Extubation Stridor After Maxillomandibular Fixation (NA)
- Cooling to Alleviate Migraine #3 (NA)
- Effect of Ipratropium Bromide on EILO (PHASE2)
- Oral Melatonin Versus Nebulized Dexmedetomidine on Emergence Agitation in Children Undergoing Adenotonsillectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nebulize %3 Sodium Chloride CI brief — competitive landscape report
- Nebulize %3 Sodium Chloride updates RSS · CI watch RSS
- Sakarya University portfolio CI